This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/26/2026
| Endpoints | TREMFYA Combined (N=279) | Placebo (N=139) | P-Value | |
|---|---|---|---|---|
| Primary endpoint - week 12, n (%) | ||||
| Clinical remissiona | 77 (28) | 9 (6) | <0.0001 | |
| Secondary endpoints - week 12, n (%) | ||||
| Clinical responseb | 183 (66) | 48 (35) | <0.0001 | |
| Symptomatic remissionc | 143 (51) | 29 (21) | <0.0001 | |
| Endoscopic improvementd | 104 (37) | 18 (13) | <0.0001 | |
| HEMIe | 85 (30) | 15 (11) | <0.0001 | |
| Endpoints | TREMFYA 400/100 mg SC q8w (N=139) | TREMFYA 400/200 mg SC q4w (N=140) | Placebo (N=139) | P-Value |
| Secondary endpoints - week 24, n (%) | ||||
| Clinical remissiona | 49 (35) | 51 (36) | 13 (9) | <0.0001 |
| Clinical responseb | 88 (63) | 86 (61) | 43 (31) | <0.0001 |
| Symptomatic remissionc | 76 (55) | 70 (50) | 35 (25) | <0.0001 |
| Endoscopic improvementd | 56 (40) | 63 (45) | 17 (12) | <0.0001 |
| Abbreviations: BL, baseline; HEMI, histo-endoscopic mucosal improvement; MES, Mayo endoscopic subscore; q4w, every 4 weeks; q8w, every 8 weeks; RBS, rectal bleeding subscore; SC, subcutaneous; SFS, stool frequency subscore. aClinical remission was defined as Mayo SFS 0 or 1 and not increased from BL, a Mayo RBS=0, and MES 0 or 1 with no friability. bClinical response was defined as ≥30% and ≥2 point decrease from BL in modified Mayo score with ≥1 point decrease from BL in RBS or RBS 0 or 1. cSymptomatic remission was defined as SFS 0 or 1 and not increased from BL and RBS=0. dEndoscopic improvement was defined as MES 0 or 1 with no friability. eHEMI was defined as histologic improvement (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue per Geboes grading system) and endoscopic improvement. | ||||
| Endpoints | BIO/JAKi/S1Pi-Naïve | BIO/JAKi/S1Pi-IR | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TREMFYA Combined SC Induction (N=164) | PBO (N=79) | TREMFYA Combined SC Induction (N=112) | PBO (N=56) | |||||||
| Primary endpoint - week 12, n (%) | ||||||||||
| Clinical remissiona | 59 (36) | 7 (9) | 18 (16) | 2 (4) | ||||||
| Secondary endpoints - week 12, n (%) | ||||||||||
| Clinical responseb | 117 (71) | 33 (42) | 64 (57) | 14 (25) | ||||||
| Symptomatic remissionc | 97 (59) | 20 (25) | 46 (41) | 8 (14) | ||||||
| Endoscopic improvementd | 75 (46) | 14 (18) | 27 (24) | 4 (7) | ||||||
| HEMIe | 63 (38) | 11 (14) | 21 (19) | 4 (7) | ||||||
| Endpoints | BIO/JAKi/S1Pi-Naïve | BIO/JAKi/S1Pi-IR | ||||||||
| TREMFYA 400/100 mg SC q8w, (N=81) | TREMFYA 400/200 mg SC q4w, (N=83) | PBO, (N=79) | TREMFYA 400/100 mg SC q8w, (N=57) | TREMFYA 400/200 mg SC q4w, (N=55) | PBO (N=56) | |||||
| Secondary endpoints - week 24, n (%) | ||||||||||
| Clinical remissiona | 40 (49) | 36 (43) | 10 (13) | 9 (16) | 15 (27) | 3 (5) | ||||
| Clinical responseb | 60 (74) | 60 (72) | 29 (37) | 27 (47) | 26 (47) | 12 (21) | ||||
| Symptomatic remissionc | 52 (64) | 48 (58) | 24 (30) | 24 (42) | 22 (40) | 9 (16) | ||||
| Endoscopic improvementd | 44 (54) | 43 (52) | 14 (18) | 11 (19) | 20 (36) | 3 (5) | ||||
| Abbreviations: BIO/JAKi/S1Pi, biologics, Janus kinase inhibitors, or sphingosine 1-phosphate inhibitors; BL, baseline; HEMI, histo-endoscopic mucosal improvement; IR, inadequate response or intolerance; MES, Mayo endoscopic subscore; PBO, placebo; q4w, every 4 weeks; q8w, every 8 weeks; RBS, rectal bleeding subscore; SC, subcutaneous; SFS, stool frequency subscore.Note: Nominal P-value for TREMFYA vs PBO. The endpoint was not controlled for multiple comparisons. Therefore, the P-value is nominal and statistical significance has not been established. aClinical remission was defined as Mayo SFS 0 or 1 and not increased from BL, a Mayo RBS=0, and MES 0 or 1 with no friability. bClinical response was defined as ≥30% and ≥2 point decrease from BL in modified Mayo score with ≥1 point decrease from BL in RBS or RBS 0 or 1. cSymptomatic remission was defined as SFS 0 or 1 and not increased from BL and RBS=0. dEndoscopic improvement was defined as MES 0 or 1 with no friability. eHEMI was defined as histologic improvement (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue per Geboes grading system) and endoscopic improvement. | ||||||||||
| Endpoints | TREMFYA Combined (N=279) | PBO (N=139) | Adjusted Treatment Difference (95% CI) | P-Value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Endoscopic remissiona at week 12, n (%) | 47 (17) | 5 (4) | 13 (8-18) | Nominal P-value: <0.0001 | |||||
| Histological endpoints - week 12, n (%) | |||||||||
| Histological improvementb | 146 (52) | 34 (24) | 28 (19-37) | Nominal P-value: <0.0001 | |||||
| Histological remissionc | 123 (44) | 28 (20) | 24 (15-33) | Nominal P-value: <0.0001 | |||||
| Histo-endoscopic mucosal remissiond | 40 (14) | 5 (4) | 11 (6-16) | Nominal P-value: <0.0001 | |||||
| Endpoints | TREMFYA 400/100 mg SC q8w (N=139) | TREMFYA 400/200 mg SC q4w (N=140) | PBO (N=139) | Adjusted Treatment Difference (95% CI) | P-Value | ||||
| TREMFYA 400/100 mg SC q8w vs PBO | TREMFYA 400/200 mg SC q4w vs PBO | TREMFYA 400/100 mg SC q8w vs PBO | TREMFYA 400/200 mg SC q4w vs PBO | ||||||
| Endoscopic remissiona at week 24, n (%) | 29 (21) | 36 (26) | 5 (4) | 17 (10-25) | 22 (14-30) | Nominal P-value: <0.0001 | Nominal P-value: <0.0001 | ||
| Abbreviations: CI, confidence interval; MES, Mayo endoscopic subscore; PBO, placebo; q4w, every 4 weeks; q8w, every 8 weeks. Note: Nominal P-value for TREMFYA vs PBO. The endpoint was not controlled for multiple comparisons. Therefore, the P-value is nominal and statistical significance has not been established. aEndoscopic remission was defined as MES of 0. bHistologic improvement was defined as neutrophil infiltration in <5% of crypts, absence of crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system (Geboes score ≤3.1). cHistological remission was defined as the absence of neutrophils in the mucosa (both the lamina propria and epithelium), with no crypt destruction, erosions, ulcerations, or granulation tissue according to the Geboes grading system (Geboes score ≤2B.0). dHisto-endoscopic mucosal remission was defined as combined histological remission and endoscopic remission. | |||||||||
| Placebo | TREMFYA | |||
|---|---|---|---|---|
| 400 mg SC q4w→100 mg SC q8w | 400 mg SC q4w→200 mg SC q4w | 400 mg SC Combined | ||
| Bowel domain | ||||
| Baseline (0-27) | 13.2 (4.4), N=132 | 13.1 (4.3), N=131 | 13.1 (4.1), N=130 | 13.1 (4.2), N=261 |
| Change from baseline at week 12, mean (SD) | -3.9 (5.4), N=127 | - | - | -7.5 (5.5),a N=249 |
| Change from baseline at week 24, mean (SD) | -3.4 (5.3), N=128 | -7.1 (6.0),a N=127 | -6.9 (5.8),a N=125 | - |
| Clinically meaningful improvementb at week 12, n (%) | 50 (36), N=139 | - | - | 171 (61.3),a N=279 |
| Clinically meaningful improvementb at week 24, n (%) | 37 (26.6), N=139 | 76 (54.7),a N=139 | 77 (55.0),a N=140 | - |
| Abdominal symptoms domain | ||||
| Baseline (0-12), mean (SD) | 5.2 (2.5), N=132 | 5.3 (2.5), N=131 | 5.1 (2.5), N=130 | 5.2 (2.5), N=261 |
| Change from baseline at week 12, mean (SD) | -1.3 (2.1), N=127 | - | - | -2.1 (2.8),a N=249 |
| Change from baseline at week 24, mean (SD) | -1.2 (2.0), N=128 | -2.1 (2.4),d N=127 | -2.3 (2.7),a N=125 | - |
| Clinically meaningful improvementc at week 12, n (%) | 50 (36.0), N=139 | - | - | 128 (45.9),a N=279 |
| Clinically meaningful improvementc at week 24, n (%) | 37 (26.6), N=139 | 68 (48.9),a N=139 | 68 (48.6),a N=140 | - |
| Bowel urgency | ||||
| Baseline (0-4) | 2.3 (1.1), N=132 | 2.2 (1.1), N=131 | 2.3 (1.0), N=130 | 2.2 (1.1), N=261 |
| Change from baseline at week 12, mean (SD) | -0.7 (1.2), N=127 | - | - | -1.2 (1.2),a N=249 |
| Change from baseline at week 24, mean (SD) | -0.6 (1.1), N=128 | -1.2 (1.2),a N=127 | -1.1 (1.2),a N=125 | - |
| No bowel urgencyd at week 12, n (%) | 33 (23.7), N=139 | - | - | 138 (49.5),a N=279 |
| No bowel urgencyd at week 24, n (%) | 29 (20.9), N=139 | 71 (51.1),a N=139 | 63 (45.0),a N=140 | 138 (49.5),a N=279 |
| Abdominal pain | ||||
| Baseline (0-4) | 1.7 (1.1), N=132 | 1.8 (1.1), N=131 | 1.6 (1.1), N=130 | 1.7 (1.1), N=261 |
| Change from baseline at week 12, mean (SD) | -0.6 (1.1), N=127 | - | - | -1.0 (1.1),a N=249 |
| Change from baseline at week 24, mean (SD) | -0.5 (0.9), N=128 | -0.9 (1.0),a N=127 | -0.9 (1.0),a N=125 | - |
| No abdominal paine at week 12, n (%) | 43 (30.9), N=139 | - | - | 156 (55.9),a N=279 |
| No abdominal paine at week 24, n (%) | 34 (24.5), N=139 | 72 (51.8),a N=139 | 68 (48.6),b N=140 | - |
| Note: All endpoints assessed through week 12 compared the combined TREMFYA 400 mg SC treatment arm to placebo; assessments after week 12 compared each TREMFYA SC maintenance regimen to placebo. Patients who, prior to the designated timepoint, had an ostomy or colectomy, a prohibited change in UC medications, discontinued study intervention due to lack of efficacy or an AE of worsening of UC, or met rescue criteria had their baseline value carried forward from the time of the event onward or were considered not to have met the dichotomous endpoint. For participants who discontinued study intervention due to COVID-19 related reasons (excluding COVID-19 infection) or regional crisis prior to the designated timepoint, their observed values were used, if available. Participants who discontinued study intervention due to reasons other than those described above prior to the designated timepoint had their baseline value carried forward from the time of the event onward or were considered not to have met the dichotomous endpoint. Abbreviations: AE, adverse event; COVID-19, coronavirus disease 2019; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous; SD, standard deviation; UC, ulcerative colitis; UC-PRO/SS, Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms. aNominal P-value for TREMFYA vs placebo. The endpoint was not controlled for multiple comparisons. Therefore, the P-value is nominal and statistical significance has not been established. bClinically meaningful improvement is defined as ≥5 point improvement from baseline in the bowel domain. cClinically meaningful improvement is defined as ≥1.5 point improvement from baseline in the abdominal symptoms domain. dNo bowel urgency is defined as the rounded weekly average UC-PRO/SS item 7 score=0 over eligible days within 7 days prior to the designated timepoint. UC-PRO/SS Question 7: In the past 24 hours, did you feel the need to have a bowel movement right away? eNo abdominal pain is defined as the rounded weekly average UC-PRO/SS item 8 score=0 over eligible days within 7 days prior to the designated timepoint. UC-PRO/SS Question 8: In the past 24 hours, did you feel pain in your belly? | ||||
| TREMFYA 400 mg SC→ TREMFYA 100 mg q8w | TREMFYA 400 mg SC→ TREMFYA 200 mg q4w | Placeboa | |
|---|---|---|---|
| Safety analysis set, N | 139 | 140 | 139 |
| Duration of follow-up, weeks, mean (SD) | 24.0 (1.8) | 24.2 (1.8) | 20.7 (4.4) |
| Deaths, n (%) | 0 | 0 | 1 (1)b |
| Patients with ≥1, n (%) | |||
| AE | 74 (53) | 85 (61) | 91 (65) |
| AE by severityc | |||
| Mild | 42 (30) | 48 (34) | 49 (35) |
| Moderate | 27 (19) | 30 (21) | 30 (22) |
| Severe | 5 (4) | 7 (5) | 12 (9) |
| SAE | 5 (4) | 6 (4) | 17 (12) |
| AE leading to discontinuation of study agent | 3 (2)d | 4 (3) | 12 (9)e |
| Infectionf | 33 (24) | 32 (23) | 36 (26) |
| Serious infectiong | 1 (1) | 3 (2) | 1 (1) |
| Most common AEs with TREMFYA ≥5%, n (%)h | |||
| Worsening of UC | 14 (10) | 9 (6) | 29 (21) |
| Arthralgia | 11 (8) | 7 (5) | 3 (2) |
| Upper respiratory tract infection | 10 (7) | 5 (4) | 9 (6) |
| Injection site reactions, n (%) | 7 (5) | 9 (6) | 4 (3) |
| Note: Patients are counted only once for any given event, regardless of the number of times they actually experienced the event. AEs are coded using MedDRA Version 26.1. Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; q4w, every 4 weeks; q8w, every 8 weeks; SAE, serious adverse event; SC, subcutaneous; SD, standard deviation; UC, ulcerative colitis. aIncludes all placebo patients excluding data after a patient is rescued with TREMFYA. bDue to a road traffic accident. cThe worst severity event experienced by the patient is used. dOne case of worsening UC was considered treatment-related. eOne case of high-grade dysplasia was considered treatment-related. fInfections were defined as any AE that was coded to the MedDRA system organ class “Infections and infestations.” gSerious infections comprised 1 case each of pilonidal disease (400/200 mg group) and gastroenteritis (400/100 mg group); both events were of moderate severity, did not lead to study drug interruption, and resolved. Additionally, 2 cases of appendicitis occurred in the 400/200 mg group (1 moderate and 1 severe); neither resulted in study drug interruption, and both resolved. The serious infection in the placebo group was pneumonia of moderate severity, did not interrupt study drug and resolved. hMost common AEs were defined as AEs with an incidence of >5% with TREMFYA. | |||
n (%) | Overall Population | BIO/JAKi/S1Pi-Naïve | BIO/JAKi/S1Pi-IR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TREMFYA 400 mg SC→ TREMFYA 100 mg q8w (N=139) | TREMFYA 400 mg SC→ TREMFYA 200 mg q4w (N=140) | PBO (N=139) | TREMFYA 400 mg SC→ TREMFYA 100 mg q8w (N=81) | TREMFYA 400 mg SC→ TREMFYA 200 mg q4w (N=83) | PBO (N=79) | TREMFYA 400 mg SC→ TREMFYA 100 mg q8w (N=57) | TREMFYA 400 mg SC→ TREMFYA 200 mg q4w (N=55) | PBO (N=56) | |
| Clinical remissiona | 51 (36.7)b Δ 29.5c | 60 (42.9)b Δ 35.6c | 10 (7.2) | 39 (48.1)b Δ 40.3c | 42 (50.6)b Δ 43.0c | 6 (7.6) | 12 (21.1)b Δ 13.7c | 18 (32.7)b Δ 25.2c | 4 (7.1) |
| Clinical responsed | 78 (56.1)b Δ 37.4c | 83 (59.3)b Δ 40.6c | 26 (18.7) | 52 (64.2)b Δ 39.5c | 54 (65.1)b Δ 40.8c | 19 (24.1) | 25 (43.9)b Δ 30.9c | 29 (52.7)b Δ 39.3c | 7 (12.5) |
| Endoscopic improvemente | 62 (44.6)b Δ 33.1c | 66 (47.1)b Δ 35.6c | 16 (11.5) | 46 (56.8)b Δ 44.0c | 45 (54.2)b Δ 41.7c | 10 (12.7) | 16 (28.1)b Δ 16.0c | 21 (38.2)b Δ 26.8c | 6 (10.7) |
| Endoscopic remissionf | 36 (25.9)b Δ 20.9c | 37 (26.4)b Δ 21.4c | 7 (5.0) | 27 (33.3)b Δ 26.9c | 28 (33.7)b Δ 27.5c | 5 (6.3) | 9 (15.8)b Δ 11.5c | 9 (16.4)b Δ 12.6c | 2 (3.6) |
| Symptomatic remissiong | 66 (47.5)b Δ 33.1c | 75 (53.6)b Δ 39.2c | 20 (14.4) | 47 (58.0)b Δ 38.6c | 51 (61.4)b Δ 42.3c | 15 (19.0) | 19 (33.3)b Δ 24.3c | 24 (43.6)b Δ 34.0c | 5 (8.9) |
| Histologic improvementh | 65 (46.8)b Δ 33.8c | 73 (52.1)b Δ 39.2c | 18 (12.9) | 45 (55.6)b Δ 38.6c | 50 (60.2)b Δ 43.8c | 13 (16.5) | 20 (35.1)b Δ 26.8c | 23 (41.8)b Δ 34.1c | 4 (7.1) |
| Histologic remissioni | 52 (37.4)b Δ 26.6c | 63 (45.0)b Δ 34.2c | 15 (10.8) | 35 (43.2)b Δ 29.1c | 41 (49.4)b Δ 35.5c | 11 (13.9) | 17 (29.8)b Δ 21.5c | 22 (40.0)b Δ 32.4c | 4 (7.1) |
| Note: The adjusted treatment difference was based on the common risk difference by use of the Mantel-Haenszel stratum weights and the Sato variance estimator. In the overall population, the P-values were based on the Mantel-Haenszel test, stratified by BIO/JAKi/S1Pi-IR status (Yes/No) and MES at BL (moderate [2]/severe [3]). For the BIO/JAKi/S1Pi-naïve/-IR subgroups, the P-values were stratified only by the MES at BL. Patients who, prior to week 48, had an ostomy or colectomy, a prohibited change in UC medications, discontinued study agent due to lack of efficacy or an adverse event of worsening of UC, or met rescue criteria per IWRS were considered not to have achieved any of the key efficacy endpoints shown at week 48. For patients who discontinued study agent due to COVID-19-related reasons (excluding COVID-19 infection) or regional crisis, their observed values were used, if available. Patients who discontinued study agent prior to week 48 due to other reasons were considered not to have achieved any of the efficacy endpoints shown at week 48. Patients who were missing 1 or more of the components pertaining to an endpoint at week 48 were considered not to have achieved the endpoint. Abbreviations: BIO/JAKi/S1Pi, biologics, Janus kinase inhibitors, and/or sphingosine 1-phosphate inhibitors; BL, baseline; COVID-19, coronavirus disease 2019; IR, inadequate response; IWRS, Interactive Web Response System; MES, Mayo endoscopic subscore; PBO, placebo; q4w, every 4 weeks; q8w, every 8 weeks; RBS, rectal bleeding subscore; SC, subcutaneous; SFS, stool frequency subscore; UC, ulcerative colitis. aClinical remission was defined as Mayo SFS 0 or 1 and not increased from BL, a Mayo RBS=0, and MES 0 or 1 with no friability. bNominal P-value for TREMFYA vs PBO. The endpoint was not controlled for multiple comparisons. Therefore, the P-value is nominal and statistical significance has not been established. cΔ% (adjusted treatment difference) vs PBO. dClinical response was defined as ≥30% and ≥2 point decrease from BL in modified Mayo score with ≥1 point decrease from BL in RBS or RBS 0 or 1. eEndoscopic improvement was defined as MES 0 or 1 with no friability. fEndoscopic remission was defined as MES of 0. gSymptomatic remission was defined as SFS 0 or 1 and not increased from BL and RBS=0. hHistologic improvement was defined as neutrophil infiltration in <5% of crypts; no crypt destruction; and no erosions, ulcerations, or granulation tissue per Geboes grading system. iHistologic remission was defined as absence of neutrophils from the mucosa (both lamina propria and epithelium); no crypt destruction; and no erosions, ulcerations, or granulation tissue per Geboes grading system. | |||||||||
| TREMFYA 400 mg SC→ TREMFYA 100 mg q8w (N=139) | TREMFYA 400 mg SC→ TREMFYA 200 mg q4w (N=140) | PBO (N=139) | |
|---|---|---|---|
| AEs | 308.3 | 310.7 | 357.1 |
| Serious AEs | 6.5 | 8.2 | 38.4 |
| Serious infections | 0.8 | 2.5 | 3.7 |
| Discontinuations due to AEs | 4.9 | 4.1 | 19.8 |
| Abbreviations: AE, adverse event; PBO, placebo; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous. | |||
| Endpoint | TREMFYA 400 mg SC q4w (×3)b→ TREMFYA 100 mg SC q8w | TREMFYA 400 mg SC q4w (×3)b→ TREMFYA 200 mg SC q4w | ||
|---|---|---|---|---|
| Observed | Modified NRIc | Observed | Modified NRIc | |
| Symptomatic remission,d n/N (%) | 77/94 (81.9) | 77/120 (64.2) | 82/99 (82.8) | 82/115 (71.3) |
| ADT-IR | 25/35 (71.4) | 25/47 (53.2) | 24/34 (70.6) | 24/45 (53.3) |
| ADT-naïve | 52/59 (88.1) | 52/72 (72.2) | 58/64 (90.6) | 58/69 (84.1) |
| No bowel urgency,e n/N (%) | 70/93 (75.3) | 70/120 (58.3) | 75/98 (76.5) | 75/115 (65.2) |
| No abdominal pain,f n/N (%) | 67/93 (72.0) | 67/120 (55.8) | 78/98 (79.6) | 78/115 (67.8) |
| CRP, mg/L, median | 1.10 | - | 1.50 | - |
| FCP, mg/kg, median | 142 | - | 136 | - |
| Abbreviations: ADT, advanced therapy; ADT-IR, inadequate response to or intolerance of advanced therapy (TNFα antagonists, vedolizumab, ozanimod, or approved JAK inhibitors); AE, adverse event; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; FCP, fecal calprotectin; JAK, Janus kinase; NRI, nonresponder imputation; PBO, placebo; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous; TNF, tissue necrosis factor; UC, ulcerative colitis; UC-PRO/SS, Ulcerative Colitis-Patient Reported Outcome/Signs and Symptoms. aIncludes all randomized patients who received ≥1 dose of TREMFYA (including a partial dose) at or after week 48. bTREMFYA 400 mg SC q4w at weeks 0, 4, and 8. cPatients who underwent ostomy or colectomy or discontinued study treatment due to lack of efficacy or an AE related to worsening UC, prior to week 96, were considered to have not achieved any binary efficacy endpoint at week 96. For patients who discontinued study treatment due to regional crises or COVID-19-related reasons (excluding COVID-19 infection), observed values were used when available. Patients who discontinued study treatment prior to week 96 for other reasons were considered to have not achieved any binary efficacy endpoint at week 96. Patients with insufficient data to calculate a binary efficacy endpoint at week 96 were also considered not to have achieved the endpoint. dSymptomatic remission was defined as a stool frequency subscore of 0 or 1 without any increase from baseline and a rectal bleeding subscore of 0. eNo bowel urgency was defined as a rounded daily average (within 1 week) score of 0 for question 7 of the UC-PRO/SS: “In the past 24 hours, did you feel the need to have a bowel movement right away?” fNo abdominal pain was defined as a rounded daily average (within 1 week) score of 0 for question 8 of the UC-PRO/SS: “In the past 24 hours, did you feel pain in your belly?” | ||||
| TEAEs per 100 Patient-Years | TREMFYA 400 mg SC→TREMFYA 100 mg SC q8w | TREMFYA 400 mg SC→TREMFYA 200 mg SC q4w | PBO |
|---|---|---|---|
| AEs | 266.34 | 274.05 | 289.45 |
| Serious AEs | 5.67 | 6.70 | 30.71 |
| AEs leading to drug discontinuation | 3.05 | 3.57 | 14.89 |
| Serious infections | 0.87 | 1.34 | 2.79 |
| Abbreviations: AE, adverse event; PBO, placebo; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous; TEAE, treatment-emergent adverse event. | |||
| Outcomes at Week 48, n (%) | TREMFYA Induction Respondersa (Week 12) | TREMFYA Induction Nonrespondersb (Week 12) | ||
|---|---|---|---|---|
| TREMFYA 400 mg SC q4w→ TREMFYA 100 mg SC q8w (N=91) | TREMFYA 400 mg SC q4w→ TREMFYA 200 mg SC q4w (N=89) | TREMFYA 400 mg SC q4w→ TREMFYA 100 mg SC q8w (N=44) | TREMFYA 400 mg SC q4w→ TREMFYA 200 mg SC q4w (N=43) | |
| Clinical remissionc | 47 (51.6) | 54 (60.7) | 11 (25.0) | 11 (25.6) |
| Clinical responsed | 68 (74.7) | 73 (82.0) | 25 (56.8) | 21 (48.8) |
| Endoscopic improvemente | 54 (59.3) | 59 (66.3) | 18 (40.9) | 14 (32.6) |
| Endoscopic remissionf | 32 (35.2) | 37 (41.6) | 11 (25.0) | 3 (7.0) |
| Abbreviations: q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous. aResponders were defined as patients who were in clinical response at week 12 and received treatment from week 12. bNonresponders were defined as patients who were not in clinical response and clinical remission at week 12 and received treatment from week 12. cClinical remission was defined as a Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopic subscore of 0 or 1 with no friability. dClinical response was defined as a decrease from baseline in the modified Mayo score by ≥30% and ≥2 points, with either a ≥1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. eEndoscopic improvement was defined as an endoscopy subscore of 0 or 1 with no friability. fEndoscopic remission was defined as an endoscopy subscore of 0. | ||||
| n (%) | Baseline (N=393) | Week 12 (N=387) |
|---|---|---|
| Stool frequency (>4 times daily) | 387 (98.5) | 259 (66.9) |
| Rectal bleeding score (score >0) | 382 (97.2) | 167 (43.2) |
| Bowel urgency (score >0) | 352 (89.6) | 211 (54.5) |
| Abdominal pain (score >0) | 322 (81.9) | 181 (46.8) |
| CBSR (without any bowel symptoms above) | 0 | 78 (20.2) |
| Abbreviation: CBSR, complete bowel symptomatic remission. | ||
| CBSRa at Week 12 (%) | Endoscopic Improvement and Endoscopic Remission by CBSR Status | Mayo Endoscopic Subscore by CBSR Status | Patients with Normalized HRQoLd by CBSR Status | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Endoscopic Improvementb | Endoscopic Remissionc | 0 | 1 | 2 | 3 | IBDQ Remission (Score >170) | PROMIS-29 PCS (Score ≥50) | PROMIS-29 MCS (Score ≥50) | |
| Yes | 53.9 | 26.0 | 26 | 37.7 | 27.3 | 9.1 | 87.2 | 82.1 | 76.9 |
| No | 22.7 | 9.1 | 9.1 | 18.8 | 32.1 | 39.9 | 46.3 | 48.5 | 47.6 |
| Abbreviations: CBSR, complete bowel symptomatic remission; HRQoL, health-related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; PROMIS-29 MCS, Patient-Reported Outcomes Measurement Information System-29 Mental Health Component score; PROMIS-29 PCS, Patient-Reported Outcomes Measurement Information System-29 Physical Health Component score; UC-PRO/SS, Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms. aCBSR was defined as complete resolution of rectal bleeding, bowel urgency, and abdominal pain (rounded weekly average score of 0), with a daily stool frequency of ≤4 times per day, based on UC-PRO/SS. Raw scores were used without adjustment. bEndoscopic improvement was defined as a Mayo endoscopic subscore of 0 or 1, with no friability on endoscopy. cEndoscopic remission was defined as Mayo endoscopic subscore of 0. dNormalized HRQoL was defined as a disease specific-IBDQ total score of >170 and a generic-PROMIS-29 PCS or MCS T-score of ≥50. | |||||||||
Peyrin-Biroulet et al (2025)4
| Events per 100 Patient-Years | TREMFYA 400 mg SC→ TREMFYA 100 mg q8w (N=139) | TREMFYA 400 mg SC→ TREMFYA 200 mg q4w (N=140) |
|---|---|---|
| Cmax, week 8 (μg/mL), mean (SD) | 68.9 (14.1) | 28.8 (8.81) |
| Cave, week 0-12 (μg/mL), mean (SD) | 21.1 (5.80) | 19.0 (6.13) |
| Ctrough, week 12 (μg/mL), mean (SD) | 9.91 (5.02) | 14.1 (6.27) |
| AUCweek 0-12 (day × μg/mL), mean (SD) | 1770 (487) | 1590 (515) |
| Abbreviations: AUC, area under the curve; Cave, average concentration; Cmax, maximum concentration; Ctrough, trough concentration; IV, intravenous; PK, pharmacokinetics; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous; SD, standard deviation. | ||
Venkat et al (2025) evaluated the impact of SC TREMFYA induction on molecular inflammation from baseline (week 0) to week 12 in patients with UC.5
Schreiber et al (2026)9 conducted a post-hoc analysis using unsupervised machine learning to identify clusters of patients treated with TREMFYA in the ASTRO study by response trajectories.

Abbreviations: IQR, interquartile range; SD, standard deviation.
aWeek 0, n=55; week 4, n=60; week 12, n=60; week 24, n=60; week 48, n=58.
bWeek 0, n=70; week 4, n=74; week 12, n=75; week 24, n=74; week 48, n=73.
cWeek 0, n=37; week 4, n=40; week 12, n=37; week 24, n=38; week 48, n=37.
dWeek 0, n=18; week 4, n=19; week 12, n=18; week 24, n=18; week 48, n=18.
A literature search of MEDLINE®
| 1 | Long M, Allegretti JR, Danese S, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(4):284-298. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 |
Would you like to clear and leave your conversation? Message history will be lost.